SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community debates its future price trajectory and utility, with many holders actively discussing the potential for a significant token burn as a key catalyst. Conversations are heavily polarized, featuring both optimistic bulls predicting major rallies and skeptics dismissing the asset as part of a recurring meme coin cycle.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility driven by concerns over its recent convertible notes offering and CEO stock sales, leading to community frustration regarding management execution despite the long-term potential of its Casgevy commercialization and diverse gene-editing pipeline. Investors are actively debating the likelihood of a buyout or strategic partnership, while some utilize the dip to accumulate shares based on belief in the company's strong cash position and upcoming 2026 clinical data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh an upcoming Phase 3 readout for its hereditary angioedema therapy alongside significant volatility driven by high short interest and speculative sentiment. The community is actively debating the stock's potential as a binary event, with many focused on the interplay between clinical trial expectations, short-squeeze potential, and broader biotech sector momentum.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing heavy selling pressure as investors grapple with heightened competition from new AI design tools, fueling fears that its core software platform is becoming increasingly replaceable. The community remains deeply divided, with many debating whether the stock is a 'falling knife' headed for single digits or a generational buying opportunity for those betting on its long-term enterprise stickiness.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant management overhaul that includes the removal of CEO Peter Greenleaf and a total leadership restructuring led by the company's largest shareholder, Kevin Tang. The community is actively discussing the potential for an accelerated buyout and a strategic pivot to maximize shareholder value following these executive departures.

Beamable Network is a decentralized compute infrastructure designed to power real games and digital experiences. Built by the team behind Beamable Inc.—a backend platform already serving over 95 live games—the network transforms compute into an open, tokenized marketplace. By combining distributed node operators, verifiable workloads, and blockchain incentives, Beamable Network provides scalable, cost-efficient infrastructure for any compute applications without dependence on centralized cloud providers.

Beamable Network Token

Beamable Network Token is seeing significant volatility and speculative interest, with traders actively debating its potential for rapid price surges and breakout momentum. While some community members are aggressive in promoting the token as a high-reward trade, others caution the market about the risks associated with the coin's liquidity and short-term price swings.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors weigh significant technological milestones against the challenges of a complex FAA certification process and sector-wide volatility. The community remains deeply divided, with long-term bulls highlighting institutional support and progress in military and commercial demonstrations, while vocal critics focus on cash burn, ongoing legal disputes with competitors, and broader geopolitical risks impacting future operations.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors position for the upcoming May 31 PDUFA date for its ADHD candidate, CTx-1301, while closely monitoring for the imminent official grant of a U.S. patent. The community is actively debating the stock's volatility and the impact of potential manufacturing-related FDA inquiries versus the long-term potential of the firm's precision-timed release technology.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors closely monitor developments surrounding its Mears Silicon Technology (MST), with high trading volume and active speculation regarding potential licensing agreements with major semiconductor manufacturers. Community discussion is heavily focused on the company's recent capital raise, its role in improving transistor performance for next-generation nodes, and strong anticipation that upcoming results will finally catalyze a significant valuation shift.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending as investors gear up for the upcoming release of topline secondary endpoint data from its Phase 2/3 trial of tovecimig, a key binary event for the company. Community members are actively debating the potential outcomes, with sentiment split between optimism over the clinical trial's progress and caution regarding the inherent risks of biotech binary events.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The manufacturing sector has been in a recession since November 2022, according to the Institute for Supply Management’s (ISM) manufacturing purchasing managers’ index (PMI). There could be light at the end of the tunnel, with a new administration taking charge in a little under three months following Donald Trump’s convincing win in the 2024 presidential election.Down In DumpsThe ISM’s manufacturing PMI has been below the “50” cut-off mark that separates expansion and contraction for 23 months since Nov. 2022 and barely expanded in a month in the interim (March 2024).<figure class="image"><img style="aspect-ratio:1182/532;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ism_ycharts_e9baa61ddf.png" alt="ism-ycharts.png" width="1182" height="532"><figcaption>Source: Y Charts</figcaption></figure>The latest manufacturing PMI reading came in at 46.5 for October, which marked the fastest contraction since July 2023.Timothy Fiore, chair of the ISM, said,&nbsp;“U.S. manufacturing activity contracted again in October, and at a faster rate compared to last month. Demand continues to be weak, output declined, and inputs stayed accommodative.”He attributed the predicament to contractions in new orders and backlog of orders, and depressed customer inventory levels."Demand remains subdued, as companies continue to show an unwillingness to invest in capital and inventory due to concerns (for example, inflation resurgence) about federal monetary policy direction in light of the fiscal policies proposed by both major parties," Fiore said.The manufacturing sector’s contribution to GDP has been on the decline, accounting for just 10% of the total GDP in the second quarter of 2024.<figure class="image"><img style="aspect-ratio:1320/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/fredgraph_manufact_f106ee66ae.png" alt="fredgraph - manufact.png" width="1320" height="450"><figcaption>Source: St. Louis Fed</figcaption></figure>Revival In CardsIn a campaign speech in North Carolina in late September, Trump&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://tribune.com.pk/story/2498698/trump-promises-us-manufacturing-revival-in-north-carolina-speech">promised</a> to bring about a “manufacturing renaissance” by reducing taxes, reducing energy costs, and easing regulations to attract jobs from other countries.Fund manager Louis Navellier said in a recent note to clients that the manufacturing sector is on track to turn around.If the new administration can help the sector to expand via tariffs against unfair competition overseas and work toward lowering energy prices, and the Federal Reserve reduces rates, the U.S. manufacturing sector can gain a competitive advantage vis-a-vis the other nations, he said.“In theory, the U.S. should experience a manufacturing boom, especially if the natural gas industry booms and helps expand the U.S. utility grid,” Navellier said.Retail interest in the manufacturing sector has increased amid these geopolitical developments.&nbsp;Here are the most widely-tracked industrial stocks on Stocktwits and their watcher count:Boeing Co. ($BA): 188,825General Electric Co. ($GE): 151,848Caterpillar, Inc. ($CAT): 31,052Lockheed Martin Corp. ($LMT): 30,114Tellurian, Inc. ($TELL): 25,3733M Co. ($MMM): 23,617SunPower Corp. ($SPWR): 23,270RTX Corp. ($RTX): 20,148Deere &amp; Co. (DE): 12,158Kratos Defense &amp; Security Solutions, Inc. ($KTOS): 12,158Axon Enterprises, Inc. ($AXON): 10,969Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-stock-gains-on-positive-regulatory-update-on-obesity-candidate/cJ45TcSRa9">Altimmune Stock Jumps As Obesity Drug Candidate Clears Key FDA Meeting: Retail Bulls Charge In</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Manufacturing sector currently contribute to 10% of GDP.

Can Trump Make Manufacturing Great Again? 11 Stocks Retail Is Closely Watching

The ISM’s manufacturing PMI has been below the “50” cut-off mark that separates expansion and contraction for 23 of the 24 months since Nov. 2022

Equity

The ISM’s manufacturing PMI has been below the “50” cut-off mark that separates expansion and contraction for 23 of the 24 months since Nov. 2022


American natural gas company Tellurian Inc (TELL) <a href="https://ir.tellurianinc.com/press-releases/detail/292/tellurian-announces-approval-of-merger-agreement-proposal">announced</a> on Friday its shareholders have approved the acquisition of the firm by Australian energy producer Woodside Energy Group (WDS).In July, Tellurian had <a href="https://ir.tellurianinc.com/press-releases/detail/291/tellurian-to-be-acquired-by-woodside-for-approximately-900">announced</a> that Woodside will acquire all outstanding shares of the firm for $1 per share in an all-cash transaction.Tellurian had stated that the acquisition price represented a 75% premium to its closing price on July 19, 2024, and a 48% premium to its 30-day volume weighted average price. According to the firm, the price reflected Driftwood LNG’s premier site, fully permitted status, advanced stage of pre-FID development and strong relationships with Bechtel, Baker Hughes, and Chart.The implied total enterprise value of the transaction, including net debt, stood at approximately $1.2 billion.Following the development, retail sentiment on Stocktwits dipped into the ‘bearish territory’ as of 10:36 a.m. ET, accompanied by ‘extremely high’ message volumes (87/100).<figure class="image"><a href="https://stocktwits.com/symbol/TELL"><img style="aspect-ratio:1878/516;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_04_at_11_07_08_AM_e4e6f80670.png" alt=" Tellurian’s sentiment meter as of 10:39 a.m. ET on Oct. 04, 2024" width="1878" height="516"></a><figcaption>Tellurian’s sentiment meter as of 10:39 a.m. ET on Oct. 04, 2024</figcaption></figure>Earlier this year, the board had recommended that shareholders accept Woodside’s offer, calling it the best outcome.Executive chairman Martin Houston <a href="https://d1io3yog0oux5.cloudfront.net/_04c79007ee46ed43b7b57871a724fd44/tellurianinc/db/353/3060/pdf/Tellurian+-+Shareholder+Letter+072124.pdf">wrote</a> in his letter to shareholders that the transaction delivered substantial and certain value and highlighted that the company’s situation necessitated an exploration of all possible alternatives, including a potential sale.Notably, Tellurian is actively developing Driftwood LNG, an approximately 27.6 mtpa LNG export facility and associated pipeline network. Houston noted that Woodside’s partnership would be important in its bid to develop the facility.“The board had to thoughtfully consider the risks and costs associated with continuing to develop Driftwood on our own versus other alternatives. Ultimately, we decided the attractive offer in hand outweighed the risks and uncertainty associated with going it alone,” he said.Houston also noted that financing required to bring Driftwood into FID is contingent on commercial agreements with LNG buyers who may seek greater certainty from brownfield expansions or from project developers with larger balance sheets.Another factor that led the board to decide in favor of the acquisition was the fact that while the equity and debt required to launch Driftwood was available, fewer equity capital providers were seeking development projects in the US.“Equity providers are now less inclined to take risk ahead of projects being fully contracted. This makes the development process more sequential, and therefore extends the period over which we must self-fund,” the chairman had explained.Shares of Tellurian have gained over 29% since the beginning of the year while NYSE-listed Woodside shares have lost over 14% during the period.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zim-stock-slides-pre-market-after-jefferies-downgrade/cJcdsVuREG">ZIM Stock Sinks Over 13% After Jefferies Downgrade, End Of Dockworkers’ Strike: Retail Holds Bearish Course</a>For updates and corrections email newsroom@stocktwits.com

Earlier this year, Tellurian's board had recommended that shareholders accept Woodside’s offer, calling it the best outcome.

Tellurian Shareholders Say Yes To Acquisition By Woodside, While Retail Says No With ‘Extremely Bearish’ Outlook

In July, Tellurian had announced that Woodside will acquire all outstanding shares of the firm for $1 per share in an all-cash transaction.

Tellurian is an oil and gas exploration and production company, developing a portfolio of natural gas production, LNG marketing, and infrastructure assets that includes an LNG terminal facility and related pipelines.

TELL
Tellurian Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TELL News

TELLTellurian Inc